Why did PPGN.SW stock spike today?

The stock rose **10.07%** after PolyPeptide reported preliminary 2025 revenue of **~EUR389.00 million** and an improved **11–12% EBITDA margin**, plus capex and cash updates that reassured investors. See reporting at [Nasdaq/RTTNews](https://www.nasdaq.com/articles/polypeptide-reports-strong-prelim.

What is Meyka AI's view on PPGN.SW stock?

Meyka AI rates PPGN.SW **65.74 (Grade B, HOLD)**, citing revenue growth, margin improvement and manageable debt but noting negative EPS and high capex. The grade is model-based and not financial advice.

What near-term price target should investors use for PPGN.SW stock?

A pragmatic near-term base target is **CHF33.00** (approx **+5.92%**). Bull and bear scenarios range **CHF36.00** and **CHF28.00** respectively. Use targets alongside cash flow, guidance and upcoming earnings on 2026-03-12.

How do valuation metrics look for PPGN.SW stock?

At **CHF31.15** valuations show **P/S ~3.00**, **P/B ~3.36**, negative P/E (**-32.11**) and free cash flow yield **2.94%**, signalling priced-in recovery expectations but ongoing profitability risks.

CH Stocks

PPGN.SW stock rises 10.07% to CHF31.15 on strong 2025 results (SIX): small upside ahead

ByHuzaifa Zahoor January 20, 2026January 20, 2026

PPGN.SW stock jumped 10.07% to CHF31.15 at market close on 19 Jan 2026 after PolyPeptide Group AG reported preliminary 2025 results showing ~EUR389.00 million revenue and an 11–12% EBITDA margin. The move came on above-average volume of 124,026 shares on the SIX Swiss Exchange and follows sustained demand for metabolic therapeutics. We assess valuation, technicals and near-term upside using company metrics, sector context and Meyka AI-powered market analysis platform outputs to frame realistic price targets and risks.